By Wendy Van Sickle
Columbus, Ohio, Dec. 1 – GS Finance Corp. priced $10 million of contingent income buffered autocallable securities due Dec. 3, 2024 linked to the SPDR S&P Biotech ETF, according to a 424B2 filing with the Securities and Exchange Commission.
Investors will receive a coupon of 17.5008%, paid monthly, if the underlying ETF closes at or above its 85% downside threshold on the related observation date, plus any previously unpaid coupons.
The securities will be called automatically at par if the ETF closes at or above its initial level on any monthly observation date.
At maturity, the payout will be par unless the ETF declines by more than 15%, in which case investors will lose 1.1765% for every 1% decline beyond 15%.
The notes are guaranteed by Goldman Sachs Group, Inc.
Goldman Sachs & Co. LLC is the agent. Morgan Stanley Wealth Management is named as a dealer.
| Issuer: | GS Finance Corp.
|
| Guarantor: | Goldman Sachs Group, Inc.
|
| Issue: | Contingent income buffered autocallable securities
|
| Underlying fund: | SPDR S&P Biotech ETF
|
| Amount: | $10 million
|
| Maturity: | Dec. 3, 2024
|
| Coupon: | 17.5008%, paid monthly, if the underlying ETF closes at or above its 85% downside threshold on the related observation date, plus any previously unpaid coupons
|
| Price: | Par
|
| Payout at maturity: | Par unless the ETF declines by more than 15%, in which case investors will lose 1.1765% for every 1% decline beyond 15%
|
| Call: | Automatically at par if the ETF closes at or above its initial level on any monthly observation date
|
| Initial level: | $73.66
|
| Downside threshold: | $62.611, 85% of initial level
|
| Buffer: | 15%
|
| Downside leverage: | 117.65%
|
| Pricing date: | Nov. 27
|
| Settlement date: | Nov. 30
|
| Agent: | Goldman Sachs & Co. LLC
|
| Dealer: | Morgan Stanley Wealth Management
|
| Fees: | 0.1%
|
| Cusip: | 40057XC37
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
